Table 5.
CNS baseline and CNS efficacy and survival analysis of BM Patients.
| BRT group (n=15) | NBRT group (n=23) | p value | all patients (n=38) | |
|---|---|---|---|---|
| No (%) | No (%) | No (%) | ||
| No. of BM lesion | 0.259 | |||
| one | 2 (13.33) | 8 (34.78) | 10 (26.32) | |
| multiple | 13 (86.67) | 15 (65.22) | 28 (73.68) | |
| Characteristic of BM | 0.063 | |||
| stable | 0 (0) | 6 (26.09) | 6 (15.79) | |
| active | 15 (100) | 17 (73.91) | 32 (84.21) | |
| Best CNS response | 0.197 | |||
| CR | 6 (40.00) | 6 (26.09) | 12 (31.58) | |
| PR | 5 (33.33) | 3 (13.04) | 8 (21.05) | |
| SD | 2 (13.33) | 9 (39.13) | 11 (28.95) | |
| PD | 2 (13.33) | 5 (21.74) | 7 (18.42) | |
| CNS-ORR | 11 (73.33) | 9 (39.13) | 0.052 | 20 (52.63) |
| CNS-DCR | 13 (86.67) | 18 (78.26) | 0.681 | 31 (81.58) |
| CNS-CBR | 13 (86.67) | 10 (43.48) | 0.016* | 23 (60.53) |
| CNS-mPFS (95 %CI) | 14.37 (7.815-20.925) | 7.83 (7.047-8.613) | 0.375 | 9.77 (7.557-11.983) |
| mOS (95 %CI) a | not reached | 36.40 (18.551-54.249) | 0.034* | 36.40 (16.102-56.698) |
BM: Brain metastasis; CNS: Central nervous system; CNS-ORR: Objective response rate of the central nervous system; CNS-DCR: Central nervous system disease control rate; CNS-CBR: Clinical benefit rate of central nervous system; mPFS: Median progression free survival; mOS: Median overall survival; CI: confidence interval; a Two people were lost to follow-up in OS survival analysis.